泰州迈博太科药业有限公司成立于2015年2月，注册资本21000万美元，专注于治疗癌症和自身免疫性疾病的新药及生物类似药的研发和生产。公司现有员工300人，其中博士1位，硕士15位，本科以上学历占比60%。2021年公司研发的英夫利西单抗生物类似药CMAB008类停®成功获准上市，公司顺利实现了从研发到产业化的升级。目前公司研发的CMAB007（奥马珠单抗，用于重度哮喘治疗）已于2021年申报NDA,目前等待批准上市。CMAB009（西妥昔单抗，用于治疗转移性结直肠癌）已完成III期临床试验并已向国家药监局提交新药上市申请。CMAB807正在进行III期临床试验，CMAB819正在进行I期临床试验，另有多款产品处于临床前研究阶段。
What does 泰州迈博太科药业有限公司 require? Who is 迈博太科 hiring? 迈博太科 recruitment: 生物/制药/化工/环保类占比最多占29.7%，其次是工厂生产类占28.8%. What education can get in at 迈博太科? 本科占比最多占48.3%，其次是大专占31.4%. High education required at 迈博太科? 硕士占10.2%，博士占1.7%. Work experience required at 迈博太科? 5-10年占比最多占32.2%，其次是不限占31.4%. Where are the job locations at 迈博太科? 泰州占比最多占91.5%，其次是上海占4.2%. Based on job postings from the past year, for reference only.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
